Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center

    FRANKLIN, Mass., March 13 /CNW/ -- Echo Therapeutics (OTC Bulletin Board:  
ECTE) today announced positive results from its clinical study of the
Symphony(TM) tCGM System, a novel, non-invasive, transdermal continuous
glucose monitoring (tCGM) system, conducted at the Tufts Medical Center in
Boston, Massachusetts (Tufts). Echo is developing the Symphony tCGM System to
provide patients with diabetes and healthcare professionals with a reliable,
needle-free, wireless, continuous monitoring system to better manage diabetes
and control blood glucose levels in the home use and hospital critical care
settings. Data from the pilot study demonstrate that Symphony safely and
reliably monitored blood glucose levels in the challenging operating room and
surgical intensive care unit at Tufts. Echo is planning to present these data
at a major medical conference later this year.
    "We are proud to be the first company to report positive clinical data on
a non-invasive, transdermal continuous glucose monitoring system in the
hospital critical care setting," stated Patrick Mooney, M.D., Echo's Chairman
and CEO. "We are excited about the potential for our program in this area and
look forward to continued progress with tCGM in both the home and hospital
settings, with further studies planned throughout 2008."
    "Critically ill patients need tighter glycemic control to minimize
morbidity and mortality," said Stanley Nasraway, M.D., Director of Surgical
Intensive Care Units at Tufts and the Principal Investigator of the study.
"These data serve as a strong signal that Symphony could advance the standard
of care regarding tight glycemic control in the hospital critical care
setting, much like continuous electrocardiographic monitoring and pulse
oximetry changed standards of care in that setting. This approach could
provide doctors and nurses with breakthrough continuous blood glucometry
technology and significantly improve our ability to monitor glucose levels of
seriously ill patients in the intense intra-operative and post-operative
    Study Design
    The pilot study was designed to evaluate the performance of Echo's
current generation Symphony tCGM System, including the use of its
ultrasound-based skin permeation system and newly-improved biosensor
technology incorporating proprietary hydrogel chemistry.  The study was
performed at Tufts and enrolled twenty-five (25) adult patients scheduled for
elective cardiac surgery. The study included both intra-operative and
post-operative continuous monitoring of blood glucose (BG) levels. Two
biosensors were applied to each subject, one prior to surgery and one after
surgery. Both Symphony sensors remained on the patient for 24 hours.  BG
levels were monitored per the established protocol of Tufts. The participating
subjects and the Tufts medical staff were blinded to data collected by the
Symphony monitor.
    Analytical Methods
    In this trial, the continuous data were compared to reference
measurements from blood analyzers, glucometers and lab results based on the
Tufts glucose monitoring protocols. Those reference measurements were paired
with the Symphony results through a data analysis algorithm. The primary
statistical tools used to evaluate the performance of Symphony were Clarke
Error Grid analysis and Mean Absolute Relative Difference (MARD). The Clarke
Error Grid analysis was designed to evaluate the performance of glucometers
and is used as an analytical tool to assess performance of continuous glucose
monitors. The Clarke Error Grid is a plot of all data pairs categorized into
five discrete areas: A, B, C, D and E. The A and B areas are the most
clinically desirable zones and D and E are the least clinically desirable
zones. Devices with a higher combined A and B percentage (closer to 100%) and
lower combined D and E percentage (closer to 0) are considered to have better
performance. Monitor performance is generally considered acceptable if at
least ninety-five percent (95%) of the data points fall within the A/B region,
along with negligible or no D/E points. MARD is an error calculation tool that
measures the average relative difference between Symphony and the reference
measurements, on a percentage basis. A low MARD error, below 20%, is
consistent with an accurate device.
    Using approximately 1200 hours of continuous data from Symphony and 482
reference BG measurements from the 25 subjects, Clarke Error Grid analysis of
the study data showed that Echo's Symphony had over 97% of the data in the
combined A and B areas with approximately 70% in the "A" region, 27% in the
"B" region, and less than 3% in the "D" region.   The MARD for the study was
approximately 16%.  A total of forty-nine (49) Symphony sensors were used
during the study.  There were no Symphony failures and no adverse events,
indicating strong reliability of the Symphony for applications in the hospital
critical care setting.
    Conference Call and Webcast Information
    The Company will host a conference call at 10:30 AM ET to discuss the
data and an update of its pipeline. To access the conference call, please dial
866- 467-0407 (domestic) or 706-902-0164 (international) and reference the
conference ID 39282879. A replay of the call will be available from 10:30 a.m.
ET on March 13, until March 15, 2008, at midnight. To access the replay,
please dial 800-642-1687 (domestic) or 706-645-9291 (international) and
reference the conference ID 39282879. A live audio webcast of the call and the
archived webcast will be available in the Investors section of the Echo
Therapeutics website
    About Echo Therapeutics
    Echo Therapeutics is focused on specialty pharmaceuticals and medical
devices. Echo is developing novel topical reformulations of FDA-approved
products and non-invasive, wireless, transdermal continuous glucose monitoring
(tCGM) systems for people with diabetes and for use by healthcare
professionals in hospital critical care units worldwide.
    Cautionary Statement Regarding Forward Looking Statements
    Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any forward-
looking statements contained herein are based on current expectations, but are
subject to a number of risks and uncertainties. The factors that could cause
actual future results to differ materially from current expectations include,
but are not limited to, risks related to regulatory approvals and the success
of Echo's ongoing studies regarding the efficacy of Echo's tCGM systems, the
failure of future development and preliminary marketing efforts related to
Echo's tCGM systems, risks and uncertainties relating to Echo's ability to
develop, market and sell diagnostic products based on its skin permeation
platform technologies, the availability of substantial additional equity
capital to support robust research, development and product commercialization
activities, and the success of research, development, and regulatory approval,
marketing and distribution plans and strategies, including those plans and
strategies related to Echo's tCGM systems.  Furthermore, Echo's transdermal
continuous glucose monitoring systems have not yet been approved for sale. The
regulatory approval process for its tCGM systems involves, among other things,
successfully completing clinical trials and obtaining a premarket approval, or
PMA, from the FDA. The PMA process requires Echo to prove the safety and
efficacy of its tCGM systems to the FDA's satisfaction. This process can be
expensive and uncertain, and there is no guarantee that Echo will be able to
submit a PMA for its Symphony tCGM System or that its Symphony tCGM System
will be approved by the FDA in any specific timeframe or at all. In addition,
clinical testing of Echo's products and eventual commercialization of its
products are subject to all of the risks and uncertainties set forth in its
periodic reports filed with the Securities and Exchange Commission.
    These and other factors are identified and described in more detail in
Echo's filings with the Securities and Exchange Commission, including, without
limitation, Echo's respective annual reports on Form 10-KSB for the year ended
December 31, 2006, Echo's most recent quarterly reports on Form 10-QSB, and
Echo's current reports on Form 8-K. The foregoing list of factors is not
exhaustive. Echo Therapeutics, Inc. undertakes no obligation to publicly
update or revise any forward-looking statements.

    Investor Relations Contacts:

    Patrick T. Mooney, M.D.
    Chairman & CEO
    Echo Therapeutics

    Lilian Stern
    Stern Investor Relations

For further information:

For further information: Investor Relations, Patrick T. Mooney, M.D., 
Chairman & CEO of Echo Therapeutics, +1-508-530-0329, or Lilian Stern of Stern
 Investor Relations, +1-212-362-1200 Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890